The “Challenge” clinical study is believed to be a first for dressings, says URGO. It included 187 patients presenting with venous leg ulcers and compared the UrgoStart foam dressing with the protease inhibitor NOSF (previously known as UrgoCell Start TLC) to a neutral foam dressing without NOSF.
After two months of treatment, the healing rate in the UrgoStart group was said to be twice as fast as that of the neutral foam dressing, demonstrating its speed of woundhealing over neutral foam dressings.
